UroGen Pharma/$URGN
1D1W1MYTD1Y5YMAX
Capital at risk
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
- Ticker
- $URGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 300
- Headquarters
- Princeton, United States
- Website
- www.urogen.com
UroGen Pharma Metrics
BasicAdvanced
$2B
-
-$1.97
1.57
-
Price and volume
Market cap
$2B
Beta
1.57
52-week high
$50.81
52-week low
$15.86
Average daily volume
903K
Financial strength
Current ratio
3.802
Quick ratio
3.177
Long term debt to equity
-1.466
Total debt to equity
-1.481
Interest coverage (TTM)
-4.11%
Profitability
EBITDA (TTM)
-66.345
Gross margin (TTM)
90.85%
Net profit margin (TTM)
-51.73%
Operating margin (TTM)
-35.32%
Effective tax rate (TTM)
0.48%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-18.06%
Return on equity (TTM)
86.49%
Valuation
Price to revenue (TTM)
10.94
Price to book
-15.41
Price to tangible book (TTM)
-15.41
Price to free cash flow (TTM)
-12.975
Free cash flow yield (TTM)
-7.71%
Free cash flow per share (TTM)
-3.217
Growth
Revenue change (TTM)
100.27%
Earnings per share change (TTM)
-39.79%
3-year revenue growth (CAGR)
37.55%
3-year earnings per share growth (CAGR)
-25.16%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
Analyst projections of the future price of UroGen Pharma stock.
Bulls say / Bears say
ZUSDURI is showing strong commercial acceleration: Q2 2026 revenue reached $50.4 million, up 73% sequentially, with 1,444 activated sites, 452 prescribers and repeat prescribers representing approximately 45% of the total. Total company revenue rose to $72.5 million from $24.2 million a year earlier. (UroGen Q2 2026 results)
UGN-103 delivered a 94.5% estimated six-month duration of response in the Phase 3 UTOPIA trial, broadly consistent with ZUSDURI’s 91.9% result in ENVISION. UroGen subsequently submitted the UGN-103 NDA in August 2026, creating a near-term regulatory catalyst and potential commercial follow-on product. (UroGen UTOPIA update; UroGen NDA announcement)
UroGen’s intellectual-property position and platform optionality could extend the franchise beyond its current products: a new U.S. patent allowance is expected to protect ZUSDURI and UGN-103 into July 2044, while the IntraGel agreement provides options for up to three additional oncology products and access to TumoCure. (UroGen Q2 2026 results; UroGen-IntraGel collaboration)
UroGen remains loss-making: Q2 2026 net loss was $14.4 million, while SG&A rose to $48.4 million and interest expense reached $4.9 million after $75 million of additional borrowing. Cash, cash equivalents and marketable securities totaled $108.0 million at June 30, 2026, leaving financing and dilution risk if commercial cash generation lags expectations. (UroGen Q2 2026 results)
JELMYTO revenue fell to $22.0 million in Q2 2026 from $24.2 million a year earlier, and the company expects only 3%–7% full-year growth. Separately, Teva may sell a generic JELMYTO product beginning September 15, 2030, if approved, creating a defined long-term erosion risk. (UroGen Q2 2026 results; UroGen patent-litigation settlement)
The pipeline still carries substantial execution and regulatory risk: UGN-103 is based on a 99-patient single-arm Phase 3 study, while UGN-501 was only cleared to begin a Phase 1 trial in Q4 2026. UroGen itself cautions that trial results may not predict future outcomes and that regulatory approval is not assured. (UroGen UTOPIA update; UroGen Q2 2026 results)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
UroGen Pharma News
AllArticlesVideos
Funds containing UroGen Pharma
AllUSDEURGBP
Fund name | Fund size | $URGN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.22% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.22% |
iShares Healthcare Innovation£DRDR | £1B | 0.22% |
iShares Ageing Population€AGED | €822M | 0.18% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.